Is TuHURA Biosciences (HURA) One of the Unstoppable Stocks That Could Double Your Money?

TuHURA Biosciences Inc. (NASDAQ:HURA) is one of the 10 Unstoppable Stocks That Could Double Your Money.

TuHURA Biosciences Inc. (NASDAQ:HURA) is one of the unstoppable stocks that could double your money. TuHURA announced its financial results for Q4 and the full year. The company is advancing its Phase 3 trial for IFx-2.0 as an adjunctive treatment for Merkel Cell Carcinoma/MCC under an FDA Special Protocol Assessment, with enrollment expected to conclude in mid-2027. To support its development pipeline, TuHURA acquired Kineta’s VISTA-inhibiting antibody, TBS-2025, for $10.5 million and appointed Dr. Craig Tendler to provide oversight for clinical operations.

Significant corporate milestones include the initiation of a Phase 1b/2a study for IFx-2.0 in patients with metastatic MCC of unknown primary origin and the presentation of data at ASH identifying the Delta Opioid Receptor as a target for overcoming immunotherapy resistance. For 2026, the company expects to receive Orphan Drug Designation for IFx-2.0 in MCC and plans to meet with the FDA regarding TBS-2025’s development in AML. Additionally, TuHURA aims to select its lead antibody-drug conjugate and initiate proof-of-concept studies within the second half of the year.

Is TuHURA Biosciences (HURA) One of the Unstoppable Stocks That Could Double Your Money?

TuHURA Biosciences Inc. (NASDAQ:HURA) reported $3.6 million in cash and cash equivalents at the end of 2025, supplemented by $7.5 million received in early 2026. Annual R&D expenses rose to $20.5 million, reflecting increased investment in its clinical programs compared to the previous year. The company successfully raised $21.2 million through private placements and offerings during this period, supporting its ongoing efforts to develop novel immuno-oncology therapeutics.

TuHURA Biosciences Inc. (NASDAQ:HURA) is a clinical-stage biotech firm that develops novel immuno-oncology technologies for cancer treatment. The company was formerly known as Morphogenesis until December 2023.

While we acknowledge the risk and potential of HURA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than HURA and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.